- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Anne Bass, MD: Screening for Tuberculosis Before Starting Biologics
Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, explains why screening patients for tuberculosis before initiating biologic therapy is key.
Transcript:
Why is screening for tuberculosis before initiating treatment with a drug like infliximab so important?
Infliximab is a tumor necrosis factor inhibitor, and these agents interfere with the body’s ability to defend against certain kinds of infections, particularly viral infections and infections like [tuberculosis, TB].
Some people, particularly in Europe or people from the Caribbean, have been exposed to TB in the past, even if they didn’t actually have TB. A small amount of the bacteria stays latent in the lungs, and if you take a medicine like infliximab, the TB can become reactivated.
So, you want to make sure to know if they’ve been exposed to TB so that they can be given treatment, and then subsequently be able to take a medicine like infliximab.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
